Prolonged intermittent oral topotecan in patients with refractory and/or advanced malignancies: A phase I study

American Journal of Cancer

Volumn 3, Issue 5, 2004, Pages 317-324

  Jones, Suzanne F ^a   Kuhn, John G ^b   Greco, F Anthony ^a   Thompson, Dana S ^a   Raefsky, Eric L ^a   Patton, Jeffrey F ^a   Hainsworth, John D ^a   McKay, Charles E ^a   Greenwell, Sandra L ^a   Baker, Margaret N ^a   Burris III, Howard A ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PHENOTHIAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIARY TRACT CANCER; BODY WEIGHT; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG INTERMITTENT THERAPY; ERYTHROCYTE TRANSFUSION; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; KIDNEY DYSFUNCTION; LUNG ABSCESS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PANCYTOPENIA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SARCOMA; SEIZURE; SEPSIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; UTERUS CANCER; VOMITING;

EID: 19944426369     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200403050-00005     Document Type: Article

References (19)

1. Burns III HA, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor against human tumor colony forming units in vitro. J Natl Cancer Inst 1992; 23: 1816-20
2. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96
3. Burris III HA, Fields SM. Topoisomerase I inhibitors: an overview of the camptothecin analogs. Hematol Oncol Clin North Am 1994; 8: 333-55
4. Houghton PJ, Chesire PJ, Myer L, et al. Evaluation of 9-dimethylaminomethyl-10-hydroxy-camptothecin (topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother Pharmacol 1991; 31: 229-39
5. Houghton PJ, Chesire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitor topotecan and irinotecan administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393-403
6. Guichard S, Montazeri A, Chatelut E, et al. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation. Clin Cancer Res 2001; 7: 3222-8
7. Nakashio A, Fujita N, Rokudai S, et al. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 2000; 60: 5303-9
8. Creemers GJ, Gerrits CJH, Eckardt JR, et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997; 15: 1087-93
9. Gerrits CJH, Burris III HA, Schellens JHM, et al. Oral topotecan given once or twice daily for ten days: a phase I and pharmacology study in adult patients with solid tumors. Clin Cancer Res 1998; 4: 1153-8
10. Bowman LC, Stewart CF, Zamboni WC, et al. Toxicity and pharmacodynamics of oral topotecan in pediatric patients with relapsed solid tumors [abstract]. Proc Am Soc Clin Oncol 1996; 15: 462
11. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994; 12: 553-9
12. Creemers GJ, Gerrits CJH, Schellens JHM, et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996; 14: 2540-5
13. Gerrits CJH, Bums H, Schellens JHM, et al. Five days of oral topotecan (Hycamtin®), a phase I and pharmacological study in adult patients with solid tumors. Eur J Cancer 1998; 34: 1030-5
14. Danks MK, Pawlik CA, Whipple DO, et al. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure. Clin Cancer Res 1997; 3: 1731-8
15. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 1992; 10: 239-53
16. Minami H, Beijnen JH, Verweij J, et al. Limited sampling model for area under the concentration time curve of topotecan. Clin Cancer Res 1996; 2: 43-6
17. Fleming GF, Kugler JW, Hoffman PC, et al. Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. J Clin Oncol 1998; 16: 2032-7
18. Takimoto CH, Arbuck SG. Topoisomerase I targeting agents: the campothecins. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 579-646
19. Mould DR, Holford NHG, Schellen JHM, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002; 71: 334-48